Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis

• Register: ClinicalTrials.gov
• Last refreshed on: 16 December 2017
• Main ID: NCT03085940
• Date of registration: 07/02/2017
• Prospective Registration: No
• Primary sponsor: Indonesia University
• Public title: Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis
• Scientific title: Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis
• Date of first enrolment: January 20, 2017
• Target sample size: 37
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT03085940
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
• Phase: N/A

Countries of recruitment

Indonesia

Key inclusion & exclusion criteria

Inclusion Criteria:

- Rheumatoid Arthritis patients (2010 ACR/EULAR criteria)

- Being or will be treated with methotrexate (monotherapy)

- Agree to join the study

Exclusion Criteria:

- Autoimmune diseases other than RA

- Acute severe infection, acute coronary syndrome, heart failure, stroke

- Malignancy or chronic inflammatory diseases

- Eye disease involving the retina and visual field defects

- G6PD (glucose 6-phosphate dehydrogenase) deficiency

- History of smoking within last 5 years

- Lipid lowering, insulin resistance lowering, antidiabetic, insulin, ACE(angiotensin
converting enzyme)-inhibitor or ARB(angiotensin receptor blocker) drugs



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Rheumatoid Arthritis

Intervention(s)

Drug: Placebo

Drug: Hydroxychloroquine

Primary Outcome(s)

Endothelial dysfunction marker [Time Frame: 3 months]

Secondary ID(s)

HCQ-ED01

Source(s) of Monetary Support

Please refer to primary and secondary sponsors